Luca Durelli Clinical and Biological Sciences Department, Neurology Unit University of Torino, San Luigi Gonzaga Hospital Biography Publications Institution JoVE Articles Luca Durelli has not added a biography. If you are Luca Durelli and would like to personalize this page please email our Author Liaison for assistance. Publications Alemtuzumab Long-term Immunologic Effect: Treg Suppressor Function Increases Up to 24 Months Neurology(R) Neuroimmunology & Neuroinflammation. Feb, 2016 | Pubmed ID: 26819963 Long-term Follow-up of Ultrasound-guided Botulinum Toxin-A Injections for Sialorrhea in Neurological Dysphagia Journal of Neurology. Dec, 2015 | Pubmed ID: 26410746 Epigenetic Therapy for Friedreich Ataxia Annals of Neurology. Oct, 2014 | Pubmed ID: 25159818 Th22 Cells Are Expanded in Multiple Sclerosis and Are Resistant to IFN-β Journal of Leukocyte Biology. Dec, 2014 | Pubmed ID: 25097195 Treatment of Relapsing-remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence from an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study) JAMA Neurology. Aug, 2014 | Pubmed ID: 24977406 Use of Magnetic Resonance Imaging As Well As Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010 International Journal of MS Care. 2012 | Pubmed ID: 24453741 Th17 Cells in Multiple Sclerosis Express Higher Levels of JAK2, Which Increases Their Surface Expression of IFN-γR2 Journal of Immunology (Baltimore, Md. : 1950). Feb, 2012 | Pubmed ID: 22219326 Pro-inflammatory Cytokine and Chemokine MRNA Blood Level in Multiple Sclerosis is Related to Treatment Response and Interferon-beta Dose Journal of Neuroimmunology. Sep, 2010 | Pubmed ID: 20573405 T-helper 17 Cells Expand in Multiple Sclerosis and Are Inhibited by Interferon-beta Annals of Neurology. May, 2009 | Pubmed ID: 19475668 Risk Factors for Tumor Occurrence in Patients with Myasthenia Gravis Journal of Neurology. Aug, 2009 | Pubmed ID: 19330280 The OPTimization of Interferon for MS Study: 375 Microg Interferon Beta-1b in Suboptimal Responders Journal of Neurology. Sep, 2008 | Pubmed ID: 18825438 The Therapy of Multiple Sclerosis with Immune-modulating or Immunosuppressive Drug. A Critical Evaluation Based Upon Evidence Based Parameters and Published Systematic Reviews Clinical Neurology and Neurosurgery. Nov, 2008 | Pubmed ID: 18164542 Adherence to Interferon-beta Treatment and Results of Therapy Switching Journal of the Neurological Sciences. Aug, 2007 | Pubmed ID: 17376486 Interferon-beta1a for the Treatment of Multiple Sclerosis Expert Opinion on Biological Therapy. Apr, 2007 | Pubmed ID: 17373904 A Randomized Study of Two Interferon-beta Treatments in Relapsing-remitting Multiple Sclerosis Neurology. Dec, 2006 | Pubmed ID: 17190964 The Importance of Maintaining Effective Therapy in Multiple Sclerosis Journal of Neurology. Sep, 2005 | Pubmed ID: 16170500 Immunodetection of Anti-MAG IgM Antibody by Cross-reactivity to LA-N-1 Neuroblastoma Cells Journal of Neuroimmunology. Apr, 2005 | Pubmed ID: 15748946 Is Multiple Sclerosis a Disease That Requires Frequent Beta Interferon Dosing? Journal of Neurology. Sep, 2004 | Pubmed ID: 15378303 Anti-interferon Antibodies in Multiple Sclerosis. Molecular Basis and Their Impact on Clinical Efficacy Frontiers in Bioscience : a Journal and Virtual Library. Sep, 2004 | Pubmed ID: 15353281 High-dose, Frequently Administered Interferon Beta Therapy for Relapsing-remitting Multiple Sclerosis Must Be Maintained over the Long Term: the Interferon Beta Dose-reduction Study Journal of the Neurological Sciences. Jul, 2004 | Pubmed ID: 15240190 Dose and Frequency of Interferon Treatment Matter--INCOMIN and OPTIMS Journal of Neurology. Dec, 2003 | Pubmed ID: 14712396 Re: Vartanian T. An Examination of the Results of the EVIDENCE, INCOMIN, and Phase III Studies of Interferon Beta Products in the Treatment of Multiple Sclerosis. Clin Ther. 2003;25:105-118 Clinical Therapeutics. Jun, 2003 | Pubmed ID: 12868445 Validation of Diagnostic Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon Beta1a Annals of Neurology. Jun, 2003 | Pubmed ID: 12783417 Intravenous Immunoglobulin As First Treatment in Diabetics with Concomitant Distal Symmetric Axonal Polyneuropathy and CIDP Journal of Neurology. Jun, 2002 | Pubmed ID: 12111305 Every-other-day Interferon Beta-1b Versus Once-weekly Interferon Beta-1a for Multiple Sclerosis: Results of a 2-year Prospective Randomised Multicentre Study (INCOMIN) Lancet (London, England). Apr, 2002 | Pubmed ID: 11988242 보툴리눔 독소-A 주사를 초음파 유도 : Sialorrhea을 치료하는 방법 Pierangelo Barbero1, Marco Busso2, Carlo Alberto Artusi1, Stefania De Mercanti1, Marco Tinivella3, Andrea Veltri2, Luca Durelli1, Marinella Clerico1 1Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, 2Oncology Department, Radiology Unit, University of Torino, San Luigi Gonzaga Hospital, 3Clinical and Biological Sciences Department, Dietologic and Nutrition Unit, University of Torino, San Luigi Gonzaga Hospital Medicine
보툴리눔 독소-A 주사를 초음파 유도 : Sialorrhea을 치료하는 방법 Pierangelo Barbero1, Marco Busso2, Carlo Alberto Artusi1, Stefania De Mercanti1, Marco Tinivella3, Andrea Veltri2, Luca Durelli1, Marinella Clerico1 1Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, 2Oncology Department, Radiology Unit, University of Torino, San Luigi Gonzaga Hospital, 3Clinical and Biological Sciences Department, Dietologic and Nutrition Unit, University of Torino, San Luigi Gonzaga Hospital Medicine